Inclusion Criteria:

- Pre-menopausal

- Regular, consistent menstrual cycles

- Serum progesterone > 6 ng/ml (19 nmol/L)

- 2 months history of PBLAC score of 150-500

- Maximum of 4 type I, type II, or intramural fibroids

- Patient is at low risk for cervical cancer

- Hemoglobin > 6 g/dl

- Not at risk for pregnancy

- No desire for future fertility

- Willing and able to complete the follow-up requirements outlined in the study design
section of the protocol

- Willing to sign a consent form

Exclusion Criteria:

- Subserosal fibroids.

- Any fibroid that obstructs access to the endometrial cavity

- FSH > 20 IU/L

- Pregnancy

- Evidence of disorders of hemostasis

- Use of GnRH agonist or depomedroxyprogesterone acetate or other implantable or
injectable progestin and/or estrogen

- SERMS/SPRMS within the last 6 months

- Current use of any IUD or use of Mirena IUS within the last 3 months

- Gynecological malignancy or hyperplasia

- Known/suspected abdominal/pelvic cancer

- Active pelvic infection (e.g., active salpingitis or other pelvic inflammatory
disease)

- Adenomyosis

- Previous surgical or ablative treatment for fibroids or menorrhagia

- Previous uterine artery embolization or occlusion

- Patient on anti-coagulation therapy

- Needing emergency surgery to treat fibroid symptoms

- Concomitant intrauterine polyps.

- Major medical or psychiatric illness affecting general health or patient's ability to
comply with follow-up schedule or provide valid patient self-assessment data

- Contraindication to MRI

- Allergy to contrast media

- Mild renal insufficiency or worse

- Known renal disease

- Uncontrolled hypertension lasting 2 years or more

- Diabetes

- Uterine size > 10 weeks or 10 cm from ectocervix to fundus.